Trial results

Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes

NCT00838903 on ClinicalTrials.gov · last registry update 2017-01-09

An unusually large phase 3: 1,049 participants, more than double the 424 typical for the stage. The sponsor logged completion for January 2012. Primary outcome, as filed: Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 104. albiglutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended. The registry entry has been edited 1 time since then.

Status

COMPLETED

Phase

P3

Drug

albiglutide

Tanzeum

Sponsor

GlaxoSmithKline

Sponsor type

Industry

Enrollment

1,049

Started

2009-02

Primary completion

2012-01 actual

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 104

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the albiglutide page for this molecule’s full trial and approval history.